Medable, Inc., a Palo Alto, Calif.-based provider of a digital platform to decentralize clinical trials, raised $78m in funding.
The round was led by Sapphire Ventures, with participation from new investor Obvious Ventures and follow-on investment from existing investors GSR Ventures, PPD, Inc. (Nasdaq:PPD) and Streamlined Ventures.
The company, which has raised more than $217m to date, intends to use the funds to continue enabling broad adoption of digital trials and patient-centric strategies at global scale. Key focus areas include internal initiatives related to ubiquitous research access, patient data fluidity, and intelligent monitoring of patients and clinical trial data.
What You Should Know:
– Medable, Inc., a Palo Alto, CA-based global platform for decentralized clinical trials today announced $78M in new funding to fuel advances in the delivery of digital and decentralized clinical trials, accelerating the industry’s shift to patient-centered drug development. The funding was led by Sapphire Ventures, along with new investor Obvious Ventures and follow-on investment from existing investors GSR Ventures, PPD, Inc., and Streamlined Ventures.
– This is Medable’s third round of funding in less than a year, bringing total capital raised to more than $217 million.
Global Decentralized Clinical Trial Platform
Founded in 2015 by Dr. Michelle Longmire and Tim Smith, Medable’s flexible and modular software platform enables clinical leaders to shift from clinic-centric to patient-centric research strategies. The platform provides a unified experience for patients and clinicians, enabling recruitment, remote screening, electronic consen
Medable Secures Another $78 Million Funding to Fuel Digital Innovation for Patient-Centered Drug Development biospace.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospace.com Daily Mail and Mail on Sunday newspapers.
Share this article
SAN FRANCISCO, April 13, 2021 /PRNewswire/ The global virtual clinical trials market size is expected
to reach USD 11.5 billion by 2028, according to a new report by Grand View Research, Inc. The market is expected
to expand at a CAGR of 5.7% from 2021 to 2028. The need for patient diversity clubbed with enhanced data collection in clinical trials is boosting virtual/decentralized clinical trials (DCTs) market growth.
Key suggestions from the report:
The oncology segment held 25.0% of the market share in 2020. The increasing adoption of virtual trials especially in oncology research for the diverse population is responsible for the growth of the segment
BioSpace Movers & Shakers, April 9 biospace.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospace.com Daily Mail and Mail on Sunday newspapers.